Search company, investor...
Vyera Pharmaceuticals company logo

Vyera Pharmaceuticals

vyera.com

Stage

Divestiture

Total Raised

$90M

Investors Count

1

Deal Terms

1

Portfolio Exits

1

Funding, Valuation & Revenue

2 Fundings

Vyera Pharmaceuticals has raised $90M over 2 rounds.

Vyera Pharmaceuticals's latest funding round was a Bankrupt/Admin for on May 10, 2023.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

5/10/2023

Bankrupt/Admin

$XXM

0

FY undefined

1

8/7/2015

Series A

$XXM

$XXM

0

FY undefined

10

Date

5/10/2023

8/7/2015

Round

Bankrupt/Admin

Series A

Amount

$XXM

Investors

Valuation

$XXM

$XXM

Revenue

0

FY undefined

0

FY undefined

Sources

1

10

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Vyera Pharmaceuticals Deal Terms

1 Deal Term

Vyera Pharmaceuticals's deal structure is available for 1 funding round, including their Series A from August 07, 2015.

Round

Series A

Funding Date

$XXM

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$XXM

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$XXM

Board Voting

$XXM

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series A

$XXM

$XXM

$XXM

$XXM

Vyera Pharmaceuticals Investors

1 Investors

Vyera Pharmaceuticals has 1 investors. Martin Shkreli invested in Vyera Pharmaceuticals's Series A funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

8/7/2015

8/7/2015

1
Series A

Angel Investor (Individual)

First funding

8/7/2015

Last Funding

8/7/2015

Investor

Rounds

1
Series A

Board Seats

Type

Angel Investor (Individual)

Location

Vyera Pharmaceuticals Portfolio Exits

1 Portfolio Exit

Vyera Pharmaceuticals has 1 portfolio exit. Their latest portfolio exit was Turing Pharmaceuticals - Ketamine Program on May 04, 2016.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/4/2016

Divestiture

Turing Pharmaceuticals - Ketamine Program

$XXM

1

Date

5/4/2016

Exit

Divestiture

Companies

Turing Pharmaceuticals - Ketamine Program

Valuation

$XXM

Acquirer

Sources

1

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.